MENU
CORT
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

CORT stock forecast, quote, news & analysis

Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone... Show more

CORT
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
A.I.Advisor
a Summary for CORT with price predictions
Oct 01, 2026

CORT saw its Stochastic Oscillator leaves the overbought zone

The Stochastic Oscillator for CORT moved out of overbought territory on September 29, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 58 similar instances where the indicator exited the overbought zone. In 43 of the 58 cases the stock moved lower. This puts the odds of a downward move at 74%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for CORT moved out of overbought territory on August 26, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 46 similar instances where the indicator moved out of overbought territory. In 33 of the 46 cases, the stock moved lower in the following days. This puts the odds of a move lower at 72%.

The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CORT as a result. In 52 of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 59%.

The Moving Average Convergence Divergence Histogram (MACD) for CORT turned negative on August 26, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 33 similar instances when the indicator turned negative. In 22 of the 33 cases the stock turned lower in the days that followed. This puts the odds of success at 67%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CORT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 64%.

CORT broke above its upper Bollinger Band on September 24, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for CORT entered a downward trend on September 29, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

Following a +6.54% 3-day Advance, the price is estimated to grow further. Considering data from situations where CORT advanced for three days, in 283 of 334 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 4 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. CORT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 42 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.

The Tickeron SMR rating for this company is 76 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 99 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (17.699) is normal, around the industry mean (26.780). CORT has a moderately high P/E Ratio (256.956) as compared to the industry average of (43.395). Projected Growth (PEG Ratio) (2.660) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (15.898) is also within normal values, averaging (438.009).

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Nektar Therapeutics (NASDAQ:NKTR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.21B. The market cap for tickers in the group ranges from 58 to 133.74B. VRTX holds the highest valuation in this group at 133.74B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -4%. For the same Industry, the average monthly price growth was -14%, and the average quarterly price growth was -2%. KOD experienced the highest price growth at 196%, while CDT experienced the biggest fall at -59%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -7%. For the same stocks of the Industry, the average monthly volume growth was 21% and the average quarterly volume growth was -45%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 78
Price Growth Rating: 63
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: 0 (-100 ... +100)
View a ticker or compare two or three
CORT
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a maker of drugs for the treatment of severe psychiatric and neurological diseases

Industry Biotechnology

Industry
Pharmaceuticals Other
Address
101 Redwood Shores Parkway
Phone
+1 650 327-3270
Employees
730
Web
https://www.corcept.com
CORT saw its Stochastic Oscillator leaves the overbought zone